ArticleTzu chi medical journal
Prognostic factors for the recurrence, progression, and multiple recurrences of non-muscle-invasive bladder cancer in Eastern Taiwan.
Article in Tzu chi medical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to identify the prognostic factors that influence the recurrence, progression, and multiple recurrences of non-muscle-invasive bladder cancerr (NMIBC) based on data from the Hualien Tzu Chi Hospital, Taiwan. Materials and Methods: A retrospective cohort study enrolled patients with NMIBC diagnosed between 2005 and 2022 who underwent transurethral resection of bladder tumor (TUR-BT). Demographic, clinical, and pathological data, along with recurrence outcomes, were collected. Cox proportional hazard regression models were used to analyze the factors associated with recurrence, progression to muscle-invasive disease, and risk for multiple recurrences. Results: Overall, 199 patients were included, with a mean follow-up duration of 4.6 years. Tumors recurred in 53.8% of the patients, which further progressed to muscle-invasive bladder cancer (MIBC) in 13.1%. Multivariate Cox regression analysis identified betel nut chewing, multiple tumors, high-grade tumors, and lack of bacillus Calmette-Guérin (BCG) therapy as significant predictors of recurrence. Age, high-grade tumors, and recurrence within 3 months after the initial TUR-BT were the significant predictors of progression. Multiple tumors and early recurrence occurring within 3 months after the initial TUR-BT were significantly associated with the risk of experiencing multiple recurrences. Conclusion: This study identified multiple tumors, high-grade tumors, and BCG therapy as the significant factors associated with NMIBC recurrence, with a potential link also observed for betel nut chewing. Age, tumor grade, and early recurrence emerged as the key predictors of progression to MIBC. In addition, multiple tumors and early recurrence were linked to an increased risk of experiencing multiple recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.